Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
China Coronavirus COVID-19 Research & Development

China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light

Strong Overseas Efficacy Data

  • Analysis

Executive Summary

Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.

You may also be interested in...



China Touts First COVID Antibody Approval But Border Opening Eludes

The first antibody approval for COVID-19 in China comes amid variant threats and a continued strict Zero COVID policy.

Coronavirus Update: Brii Files US EUA For Antibody Combo

Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral. 

China Closes In On Top 10 In Global Innovation Ranking

China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.

Table

View full table

Topics

Related Companies

Tags:
China Coronavirus COVID-19 Research & Development
Latest News

Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch

Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success

Torrent’s $245m Curatio Deal Gives Pole Position In Fast-Growing Cosmetic Dermatology

China Closes In On Top 10 In Global Innovation Ranking

See All
UsernamePublicRestriction

Register

SC145440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By